This article is more than 5 years old. Information may no longer be current.
Novel therapeutics demonstrate effective treatment for blepharitis
Click Here to Manage Email Alerts
KOLOA, Hawaii — Both 1% azithromycin ophthalmic solution and tobramycin 0.3%/dexamethasone 0.05% ophthalmic suspension have been shown effective in treating blepharitis and should be considered in clinical practice, a speaker here said.
 David A. Goldman |
At Hawaiian Eye 2010, David A. Goldman, MD, said, "Patients with acute exacerbations of meibomian gland disease need an effective treatment to address their signs and symptoms. If you are not already incorporating [AzaSite and Tobradex ST] into your practice, I think you should."
In clinical studies, AzaSite (1% azithromycin ophthalmic solution, Inspire) "demonstrated significant improvements in meibomian gland plugging, meibomian gland secretions and eyelid redness," Dr. Goldman said.
In a comparison of Tobradex (tobramycin and dexamethasone, Alcon) and Tobradex ST (tobramycin 0.3%/dexamethasone ophthalmic suspension 0.05%, Alcon), a new suspension of Tobradex, data has shown only a 3% settling of Tobradex ST compared with 61% in Tobradex after 24 hours, he said.
"Tobradex ST demonstrated improved suspension formulation characteristics, enhanced pharmacokinetic distribution ... and improved bactericidal characteristics compared with Tobradex," Dr. Goldman said.
Hawaiian Eye and Retina 2011 will be held January 16-21, 2011 at the Hyatt Regency Maui Resort & Spa in Ka'anapali, Maui. Learn more at OSNHawaiianEye.com.